Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know

Steven A. Rosenberg

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma. In a pilot trial combining cell transfer with a maximum lymphodepleting regimen, complete durable responses were seen in 40% of patients, with complete responses ongoing beyond 3 to 7 years. Current approaches to cell transfer therapy using autologous cells genetically engineered to express conventional or chimeric T-cell receptors have mediated cancer regression in patients with metastatic melanoma, synovial sarcoma, neuroblastoma and refractory lymphoma. Adoptive cell transfer immunotherapy is a rapidly developing new approach to the therapy of metastatic cancer in humans. This Review will emphasize the current available applications of cell transfer immunotherapy for patients with cancer.

Original languageEnglish (US)
Pages (from-to)577-585
Number of pages9
JournalNature Reviews Clinical Oncology
Volume8
Issue number10
DOIs
StatePublished - Oct 2011

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know'. Together they form a unique fingerprint.

Cite this